Patients with the relapsing-remitting (RRMS) form of multiple sclerosis (MS) have shown improvement with glatiramer acetate (Copaxone/Teva). But researchers are still uncertain exactly how the drug works.
In research published online Sept. 29 in Jama Neurology a University of Texas Southwestern Medical Center team in Dallas, TX, reported on the ways in which glatiramer acetate affects B cells in these patients
Balance impairment in multiple sclerosis involves constraints across multiple systems and consequently necessitates multimodal treatment, according to a study published in the September issue of the Journal of Clinical Outcomes Management.
Paul Wicks, PhD, discusses the surge in Internet-savvy patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Don Mahad, MD, PhD, discusses his research’s focus of protecting nerve cells at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Alasdair Coles, MD, University of Cambridge, shares his thoughts on the efficacy of alemtuzumab for patients with multiple sclerosis (MS) at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Assessment of long-term data on treatment utility demonstrates the effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate for multiple sclerosis.